Company Search:
Advanced Search
Sponsored Links
Swedish Orphan Biovitrum AB (publ) Company Snapshot
Swedish Orphan Biovitrum AB (publ) operates in the Pharmaceutical preparations sector. In addition to historical fundamental analyses, the complete report available to purchase compares Swedish Orphan Biovitrum AB (publ) with three other pharmaceutical manufacturers in Europe: Virbac of France (2018 sales of 868.93 million Euro [US$980.74 million] ), Indivior Plc of the United Kingdom (£755.36 million [US$986.10 million] of which 100% was Buprenorphine Based Drugs), and Alkermes Plc which is based in Ireland (928.72 million Euro [US$1.05 billion] of which 100% was Pharmaceuticals).

Sales Analysis. Swedish Orphan Biovitrum AB (publ) reported sales of SEK 9.14 billion (US$987.01 million) for the year ending December of 2018. This represents an increase of 40.4% versus 2017, when the company's sales were SEK 6.51 billion. Sales at Swedish Orphan Biovitrum AB (publ) have increased during each of the previous five years (and since 2013, sales have increased a total of 320%).
Company ReportsSubscriptions
Looking For More?
Purchace an In-Depth Report
Swedish Orphan Biovitrum AB (publ)
  Stock Performance Chart for Swedish Orphan Biovitrum AB (publ)
  Stock Data: Recent Stock Performance:
  Current Price (4/12/2019): 224.60
(Figures in Swedish Kronor)
1 Week -2.6%   13 Weeks 5.5%  
4 Weeks 3.3%   52 Weeks 42.9%  
Swedish Orphan Biovitrum AB (publ) Key Data:
  Ticker: SOBI Country: Sweden
  Exchanges: FRA LON STO OTC Major Industry: Pharmaceuticals & Biotechnology
    Sub Industry: Pharmaceutical Preparations
  2018 Sales 9,139,000,000
(Year Ending Jan 2019).
Employees: 800
  Currency: Swedish Kronor Market Cap: 60,619,178,619
  Fiscal Yr Ends: December Shares Outstanding: 269,898,391
  Share Type: Aktie Closely Held Shares:
Feedback | Terms and Conditions | Privacy Policy | Site Index
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.